Dermatologists’ attitude towards psoriasis treatment during the COVID-19 pandemic
| Autor: | Paulo Ferreira, Maria João Lopes, Paulo Filipe, Marta A. Pereira, Pedro Andrade, Gabriela Marques Pinto, Martinha Henrique, Tiago Torres, Jorge Rozeira, F M Brandão, Clarisse Rebelo, Rui Tavares Bello, Hugo Gonçalo Oliveira |
|---|---|
| Přispěvatelé: | NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), Centro de Estudos de Doenças Crónicas (CEDOC) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) RM1-950 Dermatology Disease Systemic therapy Biological agents 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Quality of life (healthcare) Psoriasis Health care Pandemic Medicine 030212 general & internal medicine Original Research Pharmacology immunosuppression business.industry COVID-19 General Medicine psoriasis medicine.disease dermatology Family medicine biological agents Molecular Medicine Therapeutics. Pharmacology business Psoriasis treatment Immunosuppression |
| Zdroj: | Drugs in Context Drugs in Context, Vol 10, Pp 1-9 (2021) |
| ISSN: | 1740-4398 1745-1981 |
| Popis: | Publisher Copyright: Copyright © 2021 Torres T, Pereira M, Paiva Lopes MJ, Rebelo C, Pedro Andrade P, Henrique M, Oliveira H, Ferreira P, Marques Pinto G, Menezes Brandão F, Rozeira J, Filipe P, Tavares Bello R. Copyright: Copyright 2021 Elsevier B.V., All rights reserved. Background: The COVID-19 pandemic introduced new challenges in several dimensions in healthcare services. Herein, we describe the real-life strategies and therapeutic options adopted by dermatologists regarding their patients with psoriasis being treated with or with an indication for systemic therapy during the first COVID-19 lockdown period in Portugal. Methods: The study involves a web-based survey on the clinical management of systemic therapy for psoriasis during the COVID-19 pandemic administered to Portuguese dermatologists. The survey consisted of 55 questions (4 openended questions; 51 closed-ended questions), grouped into 6 sections. Results: A total of 60 dermatologists voluntarily participated in this survey. Nearly 63% of the participants opted for suspending biologics during the COVID-19 lockdown period and 23.3% increased the time between drug administrations. Eighty percent of the participants agreed that biologics did not change the probability of acquiring COVID-19 and 58.4% believed that these drugs decreased or did not change the severity of the disease. Approximately one-third of the participants opted not to prescribe a biological agent in patients despite clinical indication over the duration of the pandemic. Nearly 25% of the participants opted for suspending traditional immunosuppressant administration. Virtual appointments were an option for 93.3% of the participants. Conclusion: The COVID-19 pandemic has significantly affected the management of patients with psoriasis being treated with or with an indication for systemic therapy. Some of the decisions made during the first lockdown period were contrary to what we know today. These decisions might have had a significant impact on patients' quality of life and on future therapeutic success. An adequate interpretation and analysis of the available data will be extremely important to an insightful adaptation of the clinical practice in future confinement or restrictive scenarios. publishersversion published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|